Shots:
- CORE Biomedicine has entered into a licensing agreement with Eisai, securing exclusive global rights to develop & commercialize multiple preclinical oncology programs
- As per the deal, CORE will obtain exclusive, global rights to certain preclinical oncology programs spanning distinct targets & biological pathways, providing CORE with a broad pipeline to develop next-generation precision medicines
- The licensed programs, originally discovered by Eisai & its affiliates, will be advanced under CORE’s precision oncology development strategy
Ref: CORE Biomedicine | Image: CORE Biomedicine & Eisai | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
